Aurion

Aurion Biotech is a clinical-stage biotechnology company committed to developing innovative regenerative therapies aimed at restoring vision for patients suffering from ocular diseases. Headquartered in Seattle, Washington, with additional operations in Boston and Tokyo, the company's mission is to address significant unmet needs in ophthalmology through advanced cell therapy solutions. ​

Key Product – AURN001: Aurion Biotech's lead product candidate, AURN001, is an allogeneic cell therapy designed to treat corneal edema secondary to corneal endothelial disease. This condition can lead to significant vision impairment and currently lacks sufficient treatment options. AURN001 utilizes healthy donor corneal endothelial cells, expanded through a proprietary process, allowing a single donor to treat multiple patients—a significant advancement given the global shortage of donor corneas.